Indoline derivatives as 5-HT2C receptor agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 9, 2004, Pages 2367-2370

  Bentley, J M ^a   Adams, D R ^a   Bebbington, D ^a   Benwell, K R ^a   Bickerdike, M J ^a   Davidson, J E P ^a   Dawson, C E ^a   Dourish, C T ^a   Duncton, M A J ^a   Gaur, S ^a   George, A R ^a   Giles, P R ^a   Hamlyn, R J ^a   Kennett, G A ^a   Knight, A R ^a   Malcolm, C S ^a   Mansell, H L ^a   Misra, A ^a   Monck, N J T ^a   Pratt, R M ^a   Quirk, K ^a   Roffey, J R A ^a   Vickers, S P ^a   Cliffe, I A ^a   more..

^a Vernalis PLC   (United Kingdom)

Author keywords

5 HT2C; Agonist; Obesity; Serotonin

Indexed keywords

2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; ANTIOBESITY AGENT; INDOLE DERIVATIVE; RECEPTOR SUBTYPE; SEROTONIN 2C AGONIST; UNCLASSIFIED DRUG; VER 3323; VER 5384; VER 5593;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; FOOD INTAKE; LIGAND BINDING; NONHUMAN; RAT;

ANIMALS; ANTI-OBESITY AGENTS; INDOLES; RATS; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN AGONISTS;

EID: 11144357722     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.05.001     Document Type: Article

References (27)

1. Carek P.J., Dickerson L.M. Drugs. 57:1999;883-904.
2. National Center for Health Statistics, US Centers for Disease Control and Prevention. ( http://www.cdc.gov/nchs/ ).
3. Kennett G.A., Curzon G. Psychopharmacology. 96:1988;93-100.
4. Kitchener S.J., Dourish C.T. Psychopharmacology. 113:1994;369-377.
5. Walsh A.E.S., Smith K.A., Oldman A.D., Williams C., Goodall E.M., Cowen P.J. Psychopharmacology. 116:1994;120-122.
6. Sargent P.A., Sharpley A.L., Williams C., Goodall E.M., Cowen P.J. Psychopharmacology. 133:1997;309-312.
7. Tecott L.H., Sun L.M., Akana S.F., Strack A.M., Lowenstein D.H., Dallman M.F., Julius D. Nature. 374:1995;542-546.
8. Kennett G.A., Wood M.D., Bright F., Trail B., Riley G., Holland V., Avenell K.Y., Stean T., Upton N., Bromidge S., Forbes I.T., Brown A.M., Middlemiss D.N., Blackburn T.P. Neuropharmacology. 36:1997;609-620.
9. Bös M., Jenck F., Martin J.R., Moreau J.-L., Sleight A.J., Wichmann J., Widmer U. J. Med. Chem. 40:1997;2762-2769.
10. Adams, D. R.; Bentley, J. M.; Roffey, J. R. A.; Hamlyn, R. J.; Gaur, S.; Duncton, M. A. J.; Bebbington, D.; Monck, N. J.; Dawson, C. E.; Pratt, R. M.; George, A. R. Patent WO 0012475, 2000; Chem. Abstr. 2000, 132, 194289
11. Roffey, J. R. A.; Davidson, J. E. P.; Mansell, H. L.; Hamlyn, R. J.; Adams, D. R. Patent WO 0112602, 2001; Chem. Abstr. 2001, 134, 193338
12. Yang Y., Martin A.R., Nelson D.L., Regan J. Heterocycles. 34:1992;1169-1175.
13. Batcho A.D., Leimgruber W. Org. Synth. 63:1985;214-225.
14. Bitha, P.; Lin, Y. I. U.S. Patent 4,833,270, 1989; Chem. Abstr. 1989, 111, 173772
15. North, P. C.; Carter, M. C. Patent WO 9,517,405, 1995; Chem. Abstr. 1995, 123, 340087
16. Kim P.T., Guilard R., Renaut P. Can. J. Chem. 60:1982;2093-2098.
17. (b) Picart, F. European Patent 43752, 1982; Chem. Abstr. 1982, 96, 162678
18. Marburg S., Tolman R.L. J. Heterocycl. Chem. 17:1980;1333-1335.
19. Marvel C.S., Hiers G.S. Organic Syntheses Collective Volumes. Vol. 1:1941;327-330 Wiley, New York.
20. Higashiura K., Morino H., Matsuura H., Toyomaki Y., Ienaga K. J. Chem. Soc., Perkin Trans. 1. 8:1989;1479-1481.
21. (b) Rogers-Evans, M.; Soukup, M. Patent WO 9747598, 1997; Chem. Abstr. 1998, 128, 75296
22. Su D., Duan J., Chen Q. Tetrahedron Lett. 32:1991;7689-7690.
23. Porter R.H.P., Benwell K.R., Lamb H., Malcolm C.S., Allen N.H., Revell D.F., Adams D.R., Sheardown M.J. Br. J. Pharmacol. 128:1999;13-20.
24. 2A: McKenna D.J., Peroutka S.J. J. Neurosci. 9/10:1989;3482-3490.
25. 2B: Schmuck K., Ullmer C., Engels P., Lubbert H. FEBS Lett. 342:1994;85-90.
26. 2C: Hoyer D., Engel G., Kalkman H.O. Eur. J. Pharmacol. 118:1985;13-23.
27. Vickers S.P., Dourish C.T., Kennett G.A. Neuropharmacology. 41:2001;200-209.